Breast cancer is widely and effectively treated with endocrine treatment. However, in many cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype.Seven genes including AKT1, AKT2, BCAR1, BCAR2, BCAR3, EGFR2 and GRB7 have been shown to directly underlie estrogen independence in human breast cancer cells. This cell line is part of a panel of 16 cell lines (Cat No 154621-154635, 154642) which have been transfected with these genes, plus the parental (Cat No 154547).This cell line is a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity
Alternate name:
HRas Proto-Oncogene, GTPase; Transforming Protein P21
Production details:
Retroviral particles containing HRAS cDNA were produced by transient transfection of Phoenix-Ampho packaging cells using FuGENE6. ZR-75-1 cells were incubated with viral particles in the presence of 4ug/ml polybrene and 1nmol/L estradiol. Three days after transfection cells were cultured in medium containing 1umol/L 4-hydroxytamoxifen. 4-hydroxytamoxifen resistant colonies were pooled and expanded.
Cellosaurus ID:
CVCL_E4WZ
Parental cell line:
ZR-75-1
Disease:
Cancer
Cat. #:
154630
Tool sub type:
Continuous
Unit size:
1×10^6 cells / vial
Cancer types:
Breast cancer
Research Fields:
Cancer; Drug development
Organism:
Human
Tissue:
Breast
Model:
Cancer Model
Cancer Types In Detail:
Mammary ductal carcinoma
Format:
Frozen
Storage conditions:
Liquid Nitrogen
Shipping conditions:
Dry ice
Growth medium:
RPMI 1640 medium supplemented with 10% heat-inactivated bovine serum (RBCS) and 1 nM 17?-estradiol
Mycoplasma free:
Yes
Biosafety level:
1
References:
van Agthoven et al. 2010. Endocr Relat Cancer. 17(1):215-30. PMID: 19966015.
Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.
